Treatment of bacillus calmette-guérin refractory non-muscle invasive bladder cancer

No Thumbnail Available

Date

2013

Journal Title

Journal ISSN

Volume Title

Publisher

Access Rights

info:eu-repo/semantics/closedAccess

Abstract

Treatment options for patients with non-muscle invasive bladder cancer (NMIBC) refractory to intravesical bacillus Calmette-Guérin (BCG) therapy is reviewed in this article based on the recent published literature. Although intravesical BCG is the best bladder sparing treatment option for NMIBC to prevent recurrence and progression, about 1/3 of cases are refractory to this treatment. At this point radical cystectomy is the standard treatment of choice. If this option is not feasible, intravesical chemotherapy with docetaxel or gemcitabine, the combination of BCG and interferon (INF)-á or device-assisted intravesical strategies, such as mitomycin-EMDA or chemohyperthermia are some of the candidates for further treatment.

Description

Keywords

BCG failure, Itravesical therapy, Non-muscle invasive bladder cancer

Journal or Series

Archivos Espanoles de Urologia

WoS Q Value

Scopus Q Value

Q4

Volume

66

Issue

9

Citation